GLP-1 Medicines and Binge Eating Disorder: What the Liraglutide, Semaglutide and Dulaglutide Studies Show

Can GLP-1 medicines help binge eating disorder? The early answer is a cautious maybe. Small trials of liraglutide, semaglutide and dulaglutide, and a 2026 meta-analysis of 25 randomized trials, point to modest drops in binge eating, but no GLP-1 medicine has been approved for the condition and one key trial was a 27-person pilot.

Binge eating disorder means repeated episodes of eating a large amount of food in a short time while feeling unable to stop, followed by distress, without the purging seen in bulimia. Many people living with it also carry extra weight, which is how GLP-1 medicines, built for diabetes and weight loss, came into the conversation.

This article walks through what each study measured and found, how big the effects were, why eating disorder specialists are also worried about these drugs, and whether anyone has tested a low dose.

How common is binge eating disorder?

WHO World Mental Health Surveys, Kessler and colleagues, Biological Psychiatry, 2013

Binge eating disorder is the most common eating disorder. The WHO World Mental Health Surveys interviewed 24,124 adults across 14 countries and found a median lifetime prevalence of 1.4% for binge eating disorder, compared with 0.8% for bulimia nervosa.

Binge eating disorder typically starts in the late teens or early twenties, and the surveys put its median persistence at 4.3 years against 6.5 years for bulimia. The most striking finding was the treatment gap: fewer than half of people with either disorder had ever received treatment. That gap is part of why a widely prescribed drug class that changes appetite drew so much interest.

Why would a GLP-1 medicine affect binge eating?

Satiety, reward and the appetite brain

GLP-1 medicines act on satiety signalling in the brain, which is the main reason researchers expected them to dampen binges. The Richards study described semaglutide as having profound effects on central satiety signalling, and a 2026 systematic review in Pharmacotherapy listed satiety, appetite regulation and reward-driven eating as the likely routes.

That is a plausible mechanism rather than a proven one in binge eating disorder. Binges are also driven by mood, stress and the cycle of strict dieting followed by loss of control, which a drug may not touch. For background on the brain side, see our pieces on food noise on a GLP-1 and GLP-1s and dopamine.

What did the liraglutide trial for binge eating disorder find?

Allison and colleagues, Obesity Science & Practice, 2023

The liraglutide trial found that binge episodes fell in both groups, and the extra drop on liraglutide was not statistically significant. The University of Pennsylvania team randomized 27 adults with binge eating disorder and a BMI of 27 or more to liraglutide 3.0 mg daily or placebo for 17 weeks. Participants averaged 44.2 years old with a BMI of 37.9, and 63% were women.

The groups did not start level. The liraglutide group reported 4.7 objective binge episodes a week at baseline and the placebo group 3.0. By week 17, episodes had fallen by 4.0 a week on liraglutide and 2.5 a week on placebo (p = 0.37). Remission from binge eating disorder reached 44% on liraglutide and 36% on placebo, which did not differ statistically.

Weight was the clear difference: 5.2% lost on liraglutide against 0.9% on placebo. The authors flagged a pharmacy dispensing error as a significant limitation, and with only 13 people on liraglutide, the trial could easily miss a real effect or exaggerate one.

Does semaglutide help binge eating disorder?

Richards and colleagues, Obesity Pillars, 2023

Semaglutide has looked promising in one retrospective study, but it has not been tested in a randomized trial for binge eating disorder. Richards and colleagues at the University of Oklahoma reviewed the records of patients with binge eating disorder and compared three groups: semaglutide alone, lisdexamfetamine or topiramate, and semaglutide combined with one of those two.

Patients on semaglutide alone had larger reductions in Binge Eating Scale scores than the other groups, and adding lisdexamfetamine or topiramate did not improve on semaglutide alone. The pattern held in people with moderate to severe binge eating disorder. Because doctors chose who got which drug, the groups may have differed in ways the study could not adjust for, and the authors themselves called for further investigation.

What about binge eating with type 2 diabetes or bipolar disorder?

Da Porto, Diabetes & Metabolic Syndrome, 2020; Guerdjikova, Int J Psychiatry Clin Pract, 2025

In type 2 diabetes, one small open-label study favoured dulaglutide. Da Porto and colleagues randomly assigned people with type 2 diabetes and binge eating disorder, already on metformin, to dulaglutide 1.5 mg weekly or the sulfonylurea gliclazide 60 mg for 12 weeks. Binge Eating Scale scores, body weight, BMI, fat mass and HbA1c all fell more on dulaglutide. Neither patients nor doctors were blinded.

In bipolar disorder, the result was flatter. A 40-week placebo-controlled trial of liraglutide enrolled 60 people with stable bipolar disorder and obesity or overweight. A post hoc look at the 17 who also had binge eating disorder found that liraglutide (9 people) and placebo (8 people) produced similar drops in weight and Binge Eating Scale scores. The binge eating group also had more nausea or vomiting, constipation and anxiety on liraglutide. For more on GLP-1 medicines alongside psychiatric drugs, see our article on antipsychotic weight gain.

What do the 2026 meta-analyses say overall?

Emptage, EClinicalMedicine, 2026; Violante-Cumpa, Endocrine Practice, 2026

The largest meta-analysis found a real but small effect on binge eating. Emptage and colleagues at University College London pooled 25 randomized trials with 8069 participants, mostly people with obesity rather than diagnosed binge eating disorder. Compared with control, GLP-1 medicines reduced binge eating scores (g = -0.23 across 9 trials and 2106 people), eating disinhibition (g = -0.54) and emotional eating (g = -0.30). Loss of control eating fell by 18.38 points on its scale.

Two details matter. Effects were larger in trials that enrolled people with binge eating disorder, which is encouraging. Dietary restraint went up (g = 0.31), and the authors said it is unclear whether that extra restraint is healthy or pathological. All included studies were rated high risk of bias or some concerns, and heterogeneity was substantial.

A second 2026 review in Endocrine Practice, by Violante-Cumpa and colleagues, looked at approved weight loss drugs in 8 trials with 870 participants. Liraglutide (231 people) produced 4.95 kg more weight loss and fewer binge episodes in most individual studies, but the pooled effect on binge episodes was not statistically significant. Smaller reviews by Radkhah (5 studies, 182 participants) and White (12 studies, mostly under 75 participants each) reached similarly hopeful, heavily caveated conclusions.

Can GLP-1 medicines make eating disorders worse?

Keshen and colleagues, World Psychiatry, 2026

GLP-1 medicines may worsen some eating disorders, and experts now recommend screening before anyone starts one. A 2026 Delphi consensus in World Psychiatry brought together a 45-member panel of diabetes, obesity and eating disorder specialists plus people with lived experience. Recommendations needed at least 70% agreement, and average agreement was 91.7%.

The panel advised screening for current and past eating disorders with a brief validated questionnaire before prescribing, monitoring symptoms during treatment, and offering psychotherapy alongside the drug for anyone with an eating disorder. It said GLP-1 medicines should generally be avoided in active anorexia nervosa, atypical anorexia nervosa and bulimia nervosa with marked dietary restraint, and used with caution in people with a past history of these conditions.

Real-world data so far are reassuring for people with severe obesity. In a Sydney weight management program of 666 adults with class 3 obesity, Maynard and colleagues found no difference in eating disorder scores between the 59 already on a GLP-1 and those who were not. Among 31 people who started one, median weight fell from 131.0 kg to 120.0 kg over 12 months with no significant change in eating disorder or distress scores, and none stopped because of eating disorder symptoms. Our article on GLP-1 medicines and mood risk covers the wider psychiatric safety data.

How do GLP-1 medicines compare with approved binge eating treatments?

Where GLP-1 medicines sit today

GLP-1 medicines have not been compared head to head with approved treatments in a randomized trial. Lisdexamfetamine is the only medicine FDA approved for binge eating disorder, as the Richards paper notes, and it carries known abuse potential. Topiramate is commonly used off label, and psychotherapy remains a core treatment.

The White systematic review in Pharmacotherapy found adverse effects in the GLP-1 studies were mainly gastrointestinal, with no new psychiatric safety concerns, and weight changes from 3 to 24 kg. The appeal for someone with binge eating disorder and obesity is clear: one drug that might ease binges and lower weight together. The gap is that nobody yet knows whether it does the first part reliably. For the stomach side effects, our guide to GLP-1 nausea and vomiting explains when they peak.

Has a GLP-1 microdose been tested for binge eating?

What the evidence can and cannot support

No. The studies here used standard doses: liraglutide 3.0 mg daily in the Pennsylvania pilot and the bipolar trial, and dulaglutide 1.5 mg weekly in the diabetes study. None reported binge eating results at lower maintenance doses, and the semaglutide study did not report doses in its abstract.

It is tempting to assume a smaller dose would quiet the urge to binge with fewer side effects. That has not been tested. A lower dose might produce less of the satiety effect that researchers think matters, and the restraint signal in the Emptage meta-analysis is a reason to watch closely at any dose.

Binge eating disorder is a psychiatric condition, and the 2026 consensus advises pairing any GLP-1 use with eating disorder screening and, where needed, psychotherapy. Anyone considering a GLP-1 medicine with a history of binge eating should involve a clinician who treats eating disorders before starting.

Frequently Asked Questions